Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
|Articles|June 15, 2016
- BioPharm International-06-15-2016
- Volume 2016 ebook
- Issue 1
Outsourcing Industry Marked by Considerable Investments in 2016
Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.
Advertisement
The biopharmaceutical outsourcing industry has been marked by investment in technology and facility upgrades, mergers, acquisitions, and development partnerships in 2016. This article details are some of the latest developments in the biopharmaceutical outsourcing market.
Download the
Articles in this issue
over 10 years ago
Contract Service Providers Gear Up to Develop Emerging Therapiesover 10 years ago
Biopharma Service Providers Address a Full Plate of Challengesover 10 years ago
Dealing with Pharmaceutical Supply-Chain Complexitiesover 10 years ago
Keeping it Simple: Collaborating for Success in Drug Deliveryover 10 years ago
Biomanufacturers Demand Higher Quality Standards in 2016over 10 years ago
Preventing Phase III FailuresAdvertisement
Related to this article
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Advertisement
Advertisement
Trending on BioPharm International
1
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
2
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
5